Venus Medtech (Hangzhou) Inc
02500
Company Profile
Business description
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically majority of the revenue is derived from Mainland China.
Contact
No. 88, Jiangling Road
Room 311, 3rd Floor, Block 2
Binjiang District
Hangzhou310051
CHNT: +86 57187772180
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
605
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.
stocks
Tesla earnings: Shares fall as market focuses on uncertainty in near term
Are shares overpriced despite the fall?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,327.30 | 16.40 | -0.18% |
| CAC 40 | 8,225.78 | 18.91 | 0.23% |
| DAX 40 | 24,207.79 | 56.66 | 0.23% |
| Dow JONES (US) | 46,734.61 | 144.20 | 0.31% |
| FTSE 100 | 9,578.57 | 63.57 | 0.67% |
| HKSE | 25,967.98 | 186.21 | 0.72% |
| NASDAQ | 22,941.80 | 201.40 | 0.89% |
| Nikkei 225 | 49,257.42 | 615.81 | 1.27% |
| NZX 50 Index | 13,414.52 | 37.42 | 0.28% |
| S&P 500 | 6,738.44 | 39.04 | 0.58% |
| S&P/ASX 200 | 9,028.90 | 15.30 | -0.17% |
| SSE Composite Index | 3,922.41 | 8.65 | 0.22% |